DBVT
HealthcareDBV Technologies S.A. · Biotechnology · $430M
What is DBV Technologies S.A.?
DBV Technologies is a clinical-stage biopharmaceutical company based in Montrouge, France, focused on developing epicutaneous immunotherapy — treatments delivered through a skin patch rather than injections or oral doses.
DBV Technologies develops patch-based immunotherapy products designed to desensitize patients to food allergens. Its lead candidate, Viaskin Peanut, targets peanut allergy in children, adolescents, and adults and has completed Phase III clinical trials. The company is also advancing Viaskin Milk for cow's milk protein allergy and Viaskin Egg at the pre-clinical stage. Earlier-stage programs span vaccines and treatments for conditions including Crohn's disease, celiac disease, and type I diabetes.
The company was incorporated in 2002 and is headquartered in Montrouge, France.
- Viaskin Peanut — Phase III epicutaneous immunotherapy for peanut allergy
- Viaskin Milk — Phase I/II treatment for cow's milk protein allergy
- Viaskin Egg — pre-clinical therapy for hen's egg allergy
- MAG1C atopy patch test — diagnostic tool developed with Nestlé Health Science
- Early-stage vaccine and autoimmune disease research programs
Is DBVT a Good Stock to Buy?
UQS Score rates DBVT as Poor overall, reflecting the significant challenges typical of a pre-revenue, clinical-stage biopharmaceutical company.
Among the five pillars, Risk stands out as the relative bright spot — the company carries a profile that, in some respects, is less alarming than its broader score might suggest, partly due to its focused pipeline and external collaboration with Nestlé Health Science.
Quality, Moat, and Growth all register as Weak, which is consistent with a company that has no approved products, no commercial revenue, and a pipeline still dependent on regulatory outcomes. Valuation is rated Elevated, meaning the current market price may not offer a margin of safety given those uncertainties.
See the full pillar breakdown and underlying financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does DBVT pay dividends?
No — DBV Technologies S.A. does not currently pay a dividend.
DBVT does not pay a dividend, which is standard for clinical-stage biotechnology companies. All available capital is directed toward research, clinical trials, and regulatory activities. Investors in companies like DBV Technologies are typically seeking potential long-term value from pipeline success rather than current income.
When does DBVT report earnings?
DBV Technologies reports financial results on a quarterly cadence, consistent with other US-listed equities.
As a clinical-stage company, DBV Technologies does not generate product revenue, so quarterly reports focus on cash runway, operating expenses, and pipeline milestones rather than traditional earnings metrics. Progress on regulatory submissions and trial readouts tends to drive market attention more than headline financial results.
For the most recent quarter's results and pipeline updates, visit DBV Technologies' investor relations page directly.
DBVT Price History
-65.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in DBV Technologies S.A.?
Based on DBV Technologies S.A.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
DBVT Long-term Outlook
The fundamental outlook for DBVT is shaped almost entirely by regulatory and clinical outcomes. With Growth and Quality both rated Weak, the near-term trajectory depends on whether Viaskin Peanut can secure regulatory approval and whether the company can extend its cash position long enough to reach that milestone. The Elevated Valuation rating suggests the market may already be pricing in optimistic scenarios, leaving limited buffer if timelines slip.
Growth drivers
- Potential regulatory approval of Viaskin Peanut in key markets
- Expansion of the Viaskin platform into additional allergen indications
- Commercial and development collaboration with Nestlé Health Science
Key risks
- Regulatory rejection or further delays for lead pipeline candidates
- Ongoing cash burn with no product revenue to offset operating costs
- Elevated valuation leaves little room for setbacks or timeline extensions
DBVT vs Peers
DBV Technologies operates in a competitive clinical-stage landscape alongside other small-cap biotechnology and therapeutics companies.
Contineum focuses on central nervous system and inflammatory diseases, pursuing a different therapeutic area than DBV's allergen immunotherapy platform.
MiMedx develops regenerative medicine products derived from human placental tissue, giving it a commercial-stage profile that contrasts with DBV's pre-revenue status.
Lexeo is a gene therapy company targeting cardiac and neurological conditions, representing a distinct modality and disease focus compared to DBV's epicutaneous approach.
Frequently Asked Questions
What does DBV Technologies do?
DBV Technologies develops epicutaneous immunotherapy — treatments delivered via a skin patch — to desensitize patients to food allergens. Its lead program, Viaskin Peanut, has completed Phase III trials. The company also has earlier-stage programs for milk and egg allergies, as well as vaccines and autoimmune disease research.
Does DBVT pay dividends?
No, DBVT does not pay a dividend. As a clinical-stage biopharmaceutical company with no approved products, DBV Technologies directs its capital toward research and clinical development rather than shareholder distributions.
When does DBVT report earnings?
DBV Technologies reports on a quarterly cadence. Because the company has no product revenue, reports center on cash position, operating expenses, and pipeline milestones. Check the company's investor relations page for the most current schedule and recent filings.
Is DBVT a good stock to buy?
UQS Score rates DBVT as Poor overall. Quality, Moat, and Growth are all Weak, while Valuation is Elevated — a combination that signals meaningful risk for investors. The Risk pillar is the relative strength. The full pillar breakdown is available to Pro members on UQS Score.
Is DBVT overvalued?
The UQS Valuation pillar for DBVT is rated Elevated, suggesting the current market price may not adequately reflect the uncertainties around regulatory approval and the absence of commercial revenue. Clinical-stage companies often carry premium valuations based on pipeline potential, which can unwind quickly if trials disappoint.
How does DBVT compare to its competitors?
Compared to peers like Contineum Therapeutics, MiMedx, and Lexeo Therapeutics, DBV Technologies is distinguished by its epicutaneous delivery platform and allergen-focused pipeline. MiMedx has an established commercial business, while Contineum and Lexeo pursue different therapeutic areas. UQS Score provides side-by-side pillar comparisons for Pro members.
What is DBVT's market cap bracket?
DBVT is classified as a small-cap stock. This places it in a segment of the market that typically carries higher volatility and liquidity risk compared to mid- or large-cap peers, which is especially relevant for a company still in the clinical development stage.
Who founded DBV Technologies?
DBV Technologies was founded by Pierre-Henri Benhamou, Bertrand Dupont, and Christophe Dupont. The company was incorporated in 2002 and is headquartered in Montrouge, France. Further founding history is available through the company's official communications and public filings.
Is DBVT a long-term quality investment?
As a long-term quality indicator, DBVT's UQS Score of Poor — driven by Weak ratings across Quality, Moat, and Growth — signals that the company does not currently exhibit the financial durability or competitive positioning typically associated with long-term quality holdings. Regulatory success could change that picture materially.
What is the main competitive advantage of DBV Technologies?
DBV Technologies' primary differentiator is its proprietary Viaskin epicutaneous delivery platform, which aims to treat food allergies through a skin patch rather than injections or oral immunotherapy. This non-invasive approach could offer tolerability advantages, though the platform's commercial value remains contingent on regulatory approval.
What sector does DBVT belong to?
DBVT operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. Investors can explore other [healthcare stocks scored by UQS](/sector/healthcare) to compare quality profiles across the sector.
Is DBVT a growth stock or value stock?
Based on UQS pillar labels, DBVT does not fit neatly into either category. Growth is rated Weak — reflecting no commercial revenue — and Valuation is Elevated, meaning it does not screen as a traditional value opportunity either. It is best characterized as a binary clinical-stage bet.
Unlock Full DBVT Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access underlying financial metrics and trend data
- ✓Compare DBVT side-by-side with sector peers
- ✓See risk and valuation flags in full detail
- ✓Track pipeline-stage companies across Healthcare
Pro Analysis
DBVT — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 8, 2026 | 12.1 | 0.0 | 11.0 | 0.0 | 62.0 | 0.0 | -1.3 |
| Apr 22, 2026 | 13.4 | 0.0 | 11.0 | 5.9 | 63.4 | 0.0 | -0.3 |
| Apr 2, 2026 | 13.7 | 0.0 | 11.0 | 7.3 | 63.4 | 0.0 | — |
DBVT — Pillar Breakdown
Quality
— 0.0/100 (25%)DBV Technologies S.A. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)DBV Technologies S.A. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 62.0/100 (15%)DBV Technologies S.A. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)DBV Technologies S.A. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)DBV Technologies S.A. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for DBVT.
Score Composition
Financial Data
More Stock Analysis
How is the DBVT UQS Score Calculated?
The UQS (Unified Quality Score) for DBV Technologies S.A. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses DBV Technologies S.A.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether DBV Technologies S.A. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.